Telix Pharmaceuticals

Telix Pharmaceuticals

Yahoo Finance • 23 hours ago

Top 3 Australian Insider Owned Growth Stocks To Watch In October 2026

Global markets are watching central banks closely as policymakers signal that interest rates may respond to persistent inflation. Higher borrowing costs often punish weakly funded businesses, yet leave room for Australian growth companies... Full story

Yahoo Finance • 22 days ago

Biggest stock movers Monday: WBD, PSKY, META, and more

[Stock market trading growth graph] Stock futures rose Monday morning as trade optimism ahead of the U.S.-China summit and steady Middle East oil flows outweighed regional geopolitical tensions. Here are some of Monday's biggest stock mov... Full story

Yahoo Finance • 22 days ago

Telix to acquire ITM in deal worth up to $2.35bn

Australia-based Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35bn. The deal combines Telix's operations with ITM's radioisotope production business and late-stage treatmen... Full story

Yahoo Finance • 23 days ago

Telix to buy Germany’s ITM Isotope for $1.65B to expand radiopharma footprint

[Two scientists in conversation, standing in laboratory] Solskin * Australian biotechnology company Telix Pharmaceuticals (TLX [https://seekingalpha.com/symbol/TLX]) has agreed to acquire Germany's ITM Isotope in a $1.65B deal, the comp... Full story

Yahoo Finance • 25 days ago

3 Cyber Insurance Stocks Retail Investors May Want To Watch After Gemini Hacking News

When news breaks that Google's Gemini can autonomously hack real companies, the story quickly shifts from science fiction to balance sheet risk. Cyber insurance and tech liability insurers suddenly move from background players to potential... Full story

Yahoo Finance • 25 days ago

Theranostics Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)

Company Logo The global theranostics market is set for significant growth through 2036, driven by precision medicine, rising cancer prevalence, molecular imaging advances and targeted radiopharmaceutical therapies. Oncology leads adoption... Full story

Yahoo Finance • 28 days ago

Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

The race for pharmaceutical dominance often centers on chronic disease management. For investors, deciding between Novo Nordisk (NYSE:NVO) and Regeneron Pharmaceuticals (NASDAQ:REGN) requires a close look at their unique market strengths.... Full story

Yahoo Finance • 30 days ago

FDA approves Telix brain cancer imaging drug Pixclara

[Magnetic resonance imaging (MRI) or CT scan of the brain, sinusitis, sinonasal mass, brain tumours. Metastasis.] Md Babul Hosen/iStock via Getty Images The Food and Drug Administration approved Telix Pharmaceuticals’ (TLX [https://seekin... Full story

Yahoo Finance • last month

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Goldman Sachs refreshes conviction lists on both sides of the Atlantic

Investing.com -- Goldman Sachs updated its U.S. and European conviction lists for September, adding several new names as it refreshed its highest-conviction ideas heading into the autumn. In the U.S., the bank added Vertex Pharmaceuticals... Full story

Yahoo Finance • 2 months ago

Telix Pharmaceuticals Stock Leads 3 Fast Growing Insider Owned Shares

Global demand tied to AI related investment is shaping trade and capital flows, and that is putting growth companies with clear earnings ambitions back in focus. Investors are searching for businesses that can convert this demand into real... Full story

Yahoo Finance • 3 months ago

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.Consistent with previously reported results3, the publicati... Full story

Yahoo Finance • 3 months ago

Telix Pharmaceuticals Q2 Revenue Climbs Boosted By Precision Medicine Business

(RTTNews) - Telix Pharmaceuticals Limited (TLX), a radiopharmaceutical company, reported a rise in revenue for the second quarter, helped by the increased revenue from the precision medicine business. For the second quarter of fiscal 2026... Full story

Yahoo Finance • 3 months ago

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

First patient dosed in Phase 3 LUTEON1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC).LUTEON is the first Phase 3 study of a CAIX2-targeted radiopharmaceutical therapy in ccRCC. MELBOURNE (Aust... Full story

Yahoo Finance • 3 months ago

FDA Alignment to Advance ProstACT Global Phase 3 Trial

FDA and Telix align on advancement into Part 2 of the ProstACT Global Phase 3 study in the United States.FDA agrees with the clinical protocol and proposed statistical framework across three standard-of-care combination cohorts.Part 2 (ran... Full story

Yahoo Finance • 4 months ago

ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026

Telix’s first-in-class lutetium radio antibody-drug conjugate (rADC) candidate, TLX591-Tx, demonstrates acceptable tolerability across all standard-of-care (SoC) combination cohorts, with no new safety signals.Findings support feasibility... Full story

Yahoo Finance • 5 months ago

EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer

, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited (“Telix”) to explore joint clinical research ac... Full story

Yahoo Finance • 5 months ago

OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

TLX597-Tx is a PSMA1-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer.OPTIMAL-PSMA2 initial dosimetry data demonstrate low salivary gland and ki... Full story

Yahoo Finance • 6 months ago

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s piv... Full story

Yahoo Finance • 6 months ago

Telix And Regeneron Partner To Advance Next-Generation Radiopharmaceutical Therapies

(RTTNews) - Telix Pharmaceuticals Limited (TLX, TLX.AX) and Regeneron Pharmaceuticals, Inc. (REGN) have announced a collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies. This partnership brings t... Full story